USPTO Examiner MOSS NATALIE M - Art Unit 1653

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17254029USE OF AN EXTRACELLULAR MATRIX (ECM) HYDROGEL AS AN ESOPHAGEAL SUBMUCOSAL FLUID CUSHIONDecember 2020July 2022Abandon1910NoNo
17120042CANNABINOID ENRICHED COMPOSITION AND METHOD OF USINGDecember 2020October 2023Abandon3411NoNo
17089469COMPOSITIONS AND METHODS OF IMPROVING THE SKIN MICROBIOMENovember 2020January 2024Abandon3921NoNo
17075486SSCF PROCESS FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASS AND 2G RESIDUAL BIOMASSOctober 2020July 2024Abandon4420NoNo
17045110GENE THERAPY FOR OXIDATIVE STRESSOctober 2020February 2024Abandon4001NoNo
17043885USE AND DELIVERY OF AMMONIA OXIDIZING MICROORGANISMS FOR TREATMENT OF NEURODEGENERATIVE DISORDERSSeptember 2020April 2024Abandon4210NoNo
16989701HOLDERS FOR BIOREACTOR SENSORS, BIOREACTORS HAVING SUCH HOLDERS, AND METHODS CULTURING BIOLOGICAL MATERIALAugust 2020April 2023Abandon3201NoNo
16937451METHOD FOR PRODUCING ANTIGEN-SPECIFIC T CELLSJuly 2020February 2025Abandon5431NoNo
16935639TRITURATION DEVICES FOR TISSUE DISAGGREGATIONJuly 2020May 2023Abandon3301NoNo
16892156PLURIPOTENT STEM CELL-DERIVED MACROPHAGE CAPABLE OF TARGETING TUMOR CELLS AND PREPARATION METHOD THEREOFJune 2020October 2024Abandon5221NoNo
15929579BACTERIAL STRAIN COMPOSITIONS AND METHODS OF USING SAMEMay 2020July 2023Abandon3811NoNo
16648349RIBOFLAVINASE ENZYMES AND THEIR USE TO PREVENT OFF FLAVOR IN BREWINGMarch 2020October 2024Abandon5521NoNo
16806404Dosing Regimens For The Treatment Of Fabry DiseaseMarch 2020October 2023Abandon4320NoNo
16640807TRANSPOSON SYSTEM AND METHODS OF USEFebruary 2020November 2023Abandon4420NoNo
16639624Methods for Antimicrobial Susceptibility TestingFebruary 2020October 2023Abandon4430NoNo
16635142CARDIOSPHERE-DERIVED CELLS AND THEIR EXTRACELLULAR VESICLES FOR TREATMENT AND PREVENTION OF CANCERJanuary 2020May 2024Abandon5131NoNo
16751708Stable Bioactive Substances and Methods of MakingJanuary 2020April 2023Abandon3811NoNo
16710545BIOLOGICAL COMPOSITION FOR DEGRADING PLANT PESTICIDE RESIDUES AND THE APPLICATION THEREOFDecember 2019January 2024Abandon4940NoNo
16684142METHOD FOR TREATMENT OF INFERTILITY, PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFERTILITY AND METHOD FOR PRODUCING THE SAMENovember 2019March 2023Abandon4040YesNo
16603927METHODS FOR IDENTIFYING THE HEALTH STATE OF HYPOPHOSPHATASIA (HPP) PATIENTSOctober 2019April 2025Abandon6031NoNo
16540934Multilayered Vascular TubesAugust 2019December 2023Abandon5240NoNo
16532801Method of Assessing Liver Triglyceride Levels Using a Body Fluid SampleAugust 2019December 2021Abandon2810NoNo
16531605Platform for Engineered Implantable Tissues and Organs and Methods of Making the SameAugust 2019July 2024Abandon5941NoNo
16422059ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711NoNo
16422045ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019November 2020Abandon1811NoNo
16422031ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711NoNo
16422023ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711YesNo
16422052ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFMay 2019October 2020Abandon1711NoNo
16419904Process and Apparatus for Producing Mycelium BiomaterialMay 2019April 2024Abandon5950NoNo
16397159DETERMINATION OF A CONSTITUENT RELATED PROPERTY OF A MULTI-CONSTITUENT SAMPLEApril 2019June 2022Abandon3820YesNo
16382443METHOD FOR MANUFACTURING A STABLE AQUEOUS SOLUTION OF BETA-AMYLASE, AQUEOUS SOLUTION OBTAINED AND USES THEREOFApril 2019August 2022Abandon4041NoNo
16370109COMPOSITIONS FOR TREATMENT OF ATROPHIC VAGINITIS, PERI- AND POST-MENOPAUSAL DYSPAREUNIA, AND/OR OOPHORECTOMIZED FEMALES AND TREATMENT METHODS THEREWITHMarch 2019February 2024Abandon5950YesNo
16351045METHOD FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASSMarch 2019June 2024Abandon6060YesNo
16332422Lin28a ACTIVATOR AND USE THEREFORMarch 2019November 2023Abandon5740YesNo
16277571Skin Care CompositionsFebruary 2019July 2022Abandon4130NoNo
16237933COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASEJanuary 2019February 2022Abandon3740NoNo
16313359Cell enclosure device and use for sameDecember 2018July 2024Abandon6041NoNo
16216091AUTOMATED CELL COLLECTION AND SMEARINGDecember 2018February 2024Abandon6040NoNo
16209544COMPOSITION COMPRISING AN ACTIVATED MICROBIAL BIOMASSDecember 2018June 2022Abandon4241YesNo
16173536COMPOSITION USEFUL FOR THE PREPARATION OF A SUPPOSITORYOctober 2018February 2022Abandon3931NoNo
16172606ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOFOctober 2018October 2020Abandon2410NoNo
16094846Composition of proenzymes for cancer treatmentOctober 2018November 2024Abandon6061NoNo
16094384METHODS OF DEBRIDEMENT OF CHRONIC WOUNDSOctober 2018October 2024Abandon6061YesYes
16087028Device for Storing Blood and Method for Use ThereofSeptember 2018March 2023Abandon5401NoNo
16129870PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASESeptember 2018November 2024Abandon6091YesNo
16081975METHODS FOR EXPERIMENTAL EVOLUTION OF NATURAL AND SYNTHETIC MICROBESSeptember 2018May 2023Abandon5631NoNo
16074936COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTHAugust 2018November 2020Abandon2701NoNo
16071340BICOMPATIBLE PEPTIDEBIOCOMPATIBLE PEPTIDES FOR INHIBITION OF AGGREGATION OF B-AMYLOID PROTEINJuly 2018January 2025Abandon6031NoNo
15973903Compositions and Methods for Spine Fusion ProceduresMay 2018August 2021Abandon3920NoNo
15946524New A-PRP Medical Device & Tissue Engineering Composition, Manufacturing Machines And ProcessApril 2018December 2023Abandon6061YesNo
15933133PACKAGED PROBIOTIC COMPOSITION AND USES THEREOFMarch 2018June 2020Abandon2711NoNo
15927327Novel methods for delivering therapeutic agents to the eye via nasal passagesMarch 2018March 2020Abandon2420NoNo
15761396A PROCESS OF PREPARING BUCCAL EPITHELIAL CELL SUSPENSION AND ITS USEMarch 2018August 2023Abandon6031YesNo
15907417MATRIX CONSTRUCTIONFebruary 2018January 2020Abandon2220NoNo
15862201Delivery System and Probiotic Composition for Animals and PlantsJanuary 2018June 2024Allow6020NoYes
15819843METHODS OF TREATING CANCERNovember 2017August 2020Abandon3221NoNo
15819654METHOD FOR TREATMENT OF INFERTILITY, PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFERTILITY AND METHOD FOR PRODUCING THE SAMENovember 2017June 2020Abandon3131YesNo
15574250SMALL SCALE CULTIVATION METHOD FOR SUSPENSION CELLSNovember 2017July 2021Abandon4421NoNo
15782431Dosing Regimens For The Treatment Of Fabry DiseaseOctober 2017August 2020Abandon3430YesNo
15565874HUMAN MILK COMPOSITIONS AND METHODS OF MAKING AND USING SAMEOctober 2017March 2021Abandon4131NoNo
15726232HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAMEOctober 2017July 2023Abandon6060YesNo
15554886COMPOSITION FOR DIAGNOSING SKIN DAMAGE CAUSED BY FINE DUST, AND COMPOSITION COMPRISING GALANGIN AS ACTIVE INGREDIENTAugust 2017January 2022Abandon5251NoNo
15684207METHOD FOR PREPARING INDUCED MESENCHYMAL STEM CELLS AND IMPROVING MESENCHYMAL STEM CELL'S CHARACTERS AND ITS APPLICATIONSAugust 2017March 2019Abandon1811NoNo
15596940Formulations and Methods of Administration of Cephalotaxines, Including HomoharringtonineMay 2017June 2018Abandon1310NoNo
15492171REFRACTIVE INDEX MATCHING COMPOSITION FOR BIOLOGICAL TISSUEApril 2017November 2018Abandon1911NoNo
15513938THREE-DIMENSIONAL BIOPRINTED ARTIFICIAL CORNEAMarch 2017April 2019Abandon2421NoNo
15464690METHOD FOR PREPARING A DEGRADABLE MATERIALMarch 2017July 2024Abandon6081YesNo
15512003MICROFLUIDIC SYSTEM AND METHOD FOR PERFUSION BIOREACTOR CELL RETENTIONMarch 2017October 2019Abandon3221NoNo
15457013METHOD FOR REDUCING THE VISCOSITY OF A MICROORGANISM-CONTAINING SUSPENSION OR CONCENTRATEMarch 2017October 2019Abandon3111NoNo
15447974COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTIONMarch 2017May 2021Abandon5051YesNo
15436358ENHANCEMENT OF SKELETAL MUSCLE STEM CELL ENGRAFTMENT BY DUAL DELIVERY OF VEGF AND IGF-1February 2017September 2022Abandon6051NoYes
15503641PETRI DISH AND METHOD FOR THE MICROBIOLOGICAL EXAMINATION OF LIQUIDS BY MEMBRANE FILTRATIONFebruary 2017August 2021Abandon5441NoNo
15502006METHOD OF PACKAGING AMNIOTIC MEMBRANEFebruary 2017April 2018Abandon1401NoNo
15500658DETERMINATION OF A CONSTITUENT RELATED PROPERTY OF A MULTI-CONSTITUENT SAMPLEJanuary 2017January 2020Abandon3531NoNo
15329954METHOD FOR CAPTURING RARE CELLS IN BLOODJanuary 2017January 2020Abandon3620NoNo
15328656METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL LINE FROM MESENCHYMAL STEM CELLS, AND CELL LINE OBTAINED THEREBYJanuary 2017November 2022Abandon6051NoNo
15406210DRUG COCKTAIL ANALYSES USING MICROSCALE VORTEX-ASSISTED ELECTROPORATIONJanuary 2017March 2022Abandon6051YesNo
15404899MULTIPURPOSE BIOREACTORJanuary 2017February 2019Abandon2511NoNo
15400196Compositions and Related Methods For Treating HyperadrenocorticismJanuary 2017January 2021Abandon4841NoNo
15323144METHOD FOR PRODUCING OXIDIZED GAMMA-GLUTAMYLCYSTEINE AND OXIDIZED GLUTATHIONEDecember 2016August 2020Abandon4321NoNo
15394452OPTICAL BILIRUBIN SENSOR AND ASSAYDecember 2016July 2023Abandon6061NoNo
15390878METHOD FOR TREATING SPINAL CORD INJURY USING PSA-NCAM POSITIVE NEURAL CELLSDecember 2016May 2019Abandon2911NoNo
15319079METHOD FOR MAUFACTURING A STABLE AQUEOUS SOLUTION OF BETA-AMYLASE, AQUEOUS SOLUTION OBTAINED AND USES THEREOFDecember 2016December 2019Abandon3621YesYes
15318953TISSUE REGENERATION PROMOTERDecember 2016February 2020Abandon3821NoNo
15318357CULTURED CELL DIFFERENTIATION PROMOTION METHOD AND CULTURED CELL DIFFERENTIATION PROMOTERDecember 2016November 2020Abandon4741NoNo
15317351METHODS OF PROTECTION AGAINST ISCHEMIA REPERFUSION INJURYDecember 2016November 2019Abandon3521NoNo
15368224PHAGE TO TREAT BACTERIA ON SKINDecember 2016November 2020Abandon4741NoNo
15316142Assay for Oral InflammationDecember 2016July 2022Abandon6061NoNo
15362951Methods for preventing and/or treating nasal polyps and rhinosinusitisNovember 2016December 2018Abandon2420NoNo
15356950GOLD NANOPARTICLE-BASED HOMOGENEOUS COLORIMETRIC DIAGNOSTIC ASSAY FOR THE DETECTION OF PROTEASES AND PROTEASE INHIBITORSNovember 2016July 2020Abandon4321NoNo
15309420METHOD OF CULTURING CELLSNovember 2016August 2018Abandon2101NoNo
15308262MULTI-CHAMBER CULTURE VESSEL AND CELL CULTURING METHODNovember 2016February 2025Abandon6071NoYes
15306489CULTURE DISHOctober 2016May 2020Abandon4331NoNo
15292335COSMETIC SKIN TREATMENT METHODOctober 2016July 2018Abandon2220NoNo
15302373INGESTIBLE CAPSULEOctober 2016October 2019Abandon3630NoNo
15283940ARRAY OF AGE-TAILORED NUTRITIONAL FORMULA WITH PROBIOTICSOctober 2016August 2018Abandon2310NoNo
15281291SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN ANIMALSSeptember 2016July 2021Abandon5760YesYes
15126460COMPOSITIONS AND METHODS FOR TREATING RETINOPATHYSeptember 2016July 2020Abandon4671YesYes
15265706EFFERVESCENT COMPOSITION IN SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONSSeptember 2016December 2019Abandon3930NoNo
15265351Skin Care CompositionsSeptember 2016May 2019Abandon3220YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOSS, NATALIE M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
8
(61.5%)
Examiner Reversed
5
(38.5%)
Reversal Percentile
60.1%
Higher than average

What This Means

With a 38.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
49
Allowed After Appeal Filing
8
(16.3%)
Not Allowed After Appeal Filing
41
(83.7%)
Filing Benefit Percentile
20.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MOSS, NATALIE M - Prosecution Strategy Guide

Executive Summary

Examiner MOSS, NATALIE M works in Art Unit 1653 and has examined 526 patent applications in our dataset. With an allowance rate of 34.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.

Allowance Patterns

Examiner MOSS, NATALIE M's allowance rate of 34.8% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MOSS, NATALIE M receive 2.71 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MOSS, NATALIE M is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +28.4% benefit to allowance rate for applications examined by MOSS, NATALIE M. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 8.4% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 18.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 51.9% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 35.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 90.3% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.3% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.